Welcome to Awesome Blog Design perfect blog
Business, Healthcare

Merck’s KEYTRUDA® (pembrolizumab) reduced the risk of distant metastasis or death by 40% versus placebo as adjuvant treatment in resected, high-risk stage III melanoma

Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer

Business, Local News

Dodge Momentum Index inches up in August

HAMILTON, N.J.–(BUSINESS WIRE)–The Dodge Momentum Index increased 1.8% in August to 126.5 (2000=1000) from the revised July reading of 124.2. The Momentum Index, issued by Dodge Data & Analytics, is a monthly measure of the first (or initial) report for nonresidential building

Business, Healthcare

Exelixis and Catalent enter into collaboration, license, and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag® bioconjugation technology

Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with potential to extend time and scope of the collaboration Deal

Business

Movado Group, Inc. announces second quarter results

~ Second Quarter Net Sales of $88.5 million ~ ~ Second Quarter Loss Per Share of ($0.28), or ($0.07) Excluding Restructuring Plan and Other Items ~ ~ Ends Second Quarter with Cash of $170 million ~ ~ Announces Licensing Partnership with Calvin